CoChat

The role of the MDM2/p53 axis in antitumor immune responses

Brummer, Tilman, Zeiser, Robert · 2024 · Blood
Cited by 60

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Mouse double minute 2 homolog (MDM2) is a negative regulator of the tumor suppressor p53 and is often highly expressed in acute myeloid leukemia (AML) and other solid tumors. Inactivating mutations in TP53, the gene encoding p53, confers an unfavorable prognosis in AML and increases the risk for relapse after allogeneic hematopoietic cell transplantation. We review the concept that manipulation of MDM2 and p53 could enhance immunogenicity of AML and solid tumor cells. Additionally, we discuss the mechanisms by which MDM2 and p53 regulate the expression of major histocompatibility complex class I and II, transcription of double stranded RNA of endogenous retroviruses, responses of interferons, production of interleukin-15, and expression of tumor necrosis factor–related apoptosis–inducing ligand receptor 1 and 2 on malignant cells. The direct effects of MDM2 inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherapy. The preclinical findings are connected to clinical studies using MDM2 inhibition to enhance antitumor immunity in patients. This review summarizes current evidence supporting the use of MDM2 inhibition to restore p53 as well as the direct effects of MDM2 inhibition on T cells as an emerging concept for combined antitumor immunotherapy against hematological malignancies and beyond.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2023020731

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 48

  1. Vassilev, 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
  2. Hou, 2019, The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors, Cancer Cell Int, 19, 216, 10.1186/s12935-019-0937-4 · DOI · Paper page
  3. Kojima, 2005, MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy, Blood, 106, 3150, 10.1182/blood-2005-02-0553 · DOI · Paper page
  4. Muñoz-Fontela, 2008, Transcriptional role of p53 in interferon-mediated antiviral immunity, J Exp Med, 205, 1929, 10.1084/jem.20080383 · DOI · Paper page
  5. Ho, 2022, Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation, Blood, 140, 1167, 10.1182/blood.2022016082 · DOI
  6. Vadakekolathu, 2020, TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML, Blood Adv, 4, 5011, 10.1182/bloodadvances.2020002512 · DOI · Paper page
  7. Konopleva, 2022, Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial, Blood Adv, 6, 4147
  8. Langenbach, 2023, MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma, Mol Cancer Res, 21, 849, 10.1158/1541-7786.MCR-22-0898 · DOI
  9. Ahuja, 2005, SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation, Oncogene, 24, 7729, 10.1038/sj.onc.1209046 · DOI · Paper page
  10. Chène, 2001, The role of tetramerization in p53 function, Oncogene, 20, 2611, 10.1038/sj.onc.1204373 · DOI · Paper page
  11. Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  12. Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
  13. Engeland, 2022, Cell cycle regulation: p53-p21-RB signaling, Cell Death Differ, 29, 946, 10.1038/s41418-022-00988-z · DOI · Paper page
  14. Fischer, 2017, Census and evaluation of p53 target genes, Oncogene, 36, 3943, 10.1038/onc.2016.502 · DOI · Paper page
  15. Tornesello, 2018, Human oncoviruses and p53 tumor suppressor pathway deregulation at the origin of human cancers, Cancers, 10, 213, 10.3390/cancers10070213 · DOI
  16. Martinez-Zapien, 2016, Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53, Nature, 529, 541, 10.1038/nature16481 · DOI · Paper page
  17. Zeiser, 2019, Mechanisms of immune escape after allogeneic hematopoietic cell transplantation, Blood, 133, 1290, 10.1182/blood-2018-10-846824 · DOI
  18. Toffalori, 2019, Non-genomic alterations in antigen presentation and T cell costimulation are distinct drivers of leukemia immune escape and relapse after hematopoietic cell transplantation, Nat Med, 25, 603, 10.1038/s41591-019-0400-z · DOI · Paper page
  19. Christopher, 2018, Immune escape of relapsed AML cells after allogeneic transplantation, N Eng J Med, 379, 2330, 10.1056/NEJMoa1808777 · DOI · Paper page
  20. Gambacorta, 2022, Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse, Cancer Discov, 12, 1449, 10.1158/2159-8290.CD-21-0980 · DOI
  21. Gasparini, 2012, The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation, Hum Immunol, 73, 342, 10.1016/j.humimm.2012.01.018 · DOI
  22. Zhu, 1999, p53 induces TAP1 and enhances the transport of MHC class I peptides, Oncogene, 18, 7740, 10.1038/sj.onc.1203235 · DOI
  23. Falk, 2002, The final cut: how ERAP1 trims MHC ligands to size, Nat Immunol, 3, 1121, 10.1038/ni1202-1121 · doi:10.1038/ni1202-1121
  24. Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat Commun, 4, 2359, 10.1038/ncomms3359 · DOI · Paper page
  25. Zhou, 2021, Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity, Cancer Discov, 11, 3090, 10.1158/2159-8290.CD-20-1741 · DOI · Paper page
  26. Schmaltz, 2002, T cells require TRAIL for optimal graft-versus-tumor activity, Nat Med, 8, 1433, 10.1038/nm1202-797 · DOI · Paper page
  27. Lin, 2018, Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression, J Clin Invest, 128, 1708, 10.1172/JCI120803 · DOI · Paper page
  28. Prestipino, 2019, Clinical implications of tumor-intrinsic mechanisms regulating PD-L1, Sci Transl Med, 11, eaav4810, 10.1126/scitranslmed.aav4810 · DOI · Paper page
  29. Wang, 2021, Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment, Cancer Res, 81, 3079, 10.1158/0008-5472.CAN-20-0189 · DOI · Paper page
  30. Ghosh, 2021, Mutant p53 suppresses innate immune signaling to promote tumorigenesis, Cancer Cell, 39, 494, 10.1016/j.ccell.2021.01.003 · DOI · Paper page
  31. Xiao, 2022, Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy, Nat Commun, 13, 758, 10.1038/s41467-022-28279-8 · DOI · Paper page
  32. Conlon, 2015, Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer, J Clin Oncol, 33, 74, 10.1200/JCO.2014.57.3329 · DOI · Paper page
  33. Mathew, 2018, Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells, Nat Med, 24, 282, 10.1038/nm.4484 · DOI · Paper page
  34. Mastroianni, 2019, miR-146a controls immune response in the melanoma microenvironment, Cancer Res, 79, 183, 10.1158/0008-5472.CAN-18-1397 · DOI · Paper page
  35. Zhou, 2021, The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity, Nat Immunol, 22, 460, 10.1038/s41590-021-00888-3 · DOI · Paper page
  36. Mori, 2002, Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53, Oncogene, 21, 2914, 10.1038/sj.onc.1205459 · DOI · Paper page
  37. Tolcher, 2019, Phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in U.S [abstract], Mol Cancer Ther
  38. Apostolova, 2020, Extracorporeal photopheresis for severe immune checkpoint inhibitor-induced autoimmune colitis, N Eng J Med, 382, 294, 10.1056/NEJMc1912274 · DOI
  39. Daver, 2023, Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial, Blood, 141, 1265, 10.1182/blood.2022016362 · DOI
  40. Yee, 2021, Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1/1b study, Leuk Res, 100, 106489, 10.1016/j.leukres.2020.106489 · DOI · Paper page
  41. Uy, 2020, Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia, Invest New Drugs, 38, 1430, 10.1007/s10637-020-00907-4 · DOI · Paper page
  42. Stein, 2022, Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia, Clin Cancer Res, 28, 870, 10.1158/1078-0432.CCR-21-1295 · DOI · Paper page
  43. Sekiguchi, 2023, Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia, Int J Hematol, 117, 68, 10.1007/s12185-022-03464-z · DOI
  44. Erba, 2019, Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia, Blood Adv, 3, 1939, 10.1182/bloodadvances.2019030916 · DOI · Paper page
  45. Ishizawa, 2018, Predictive gene signatures determine tumor sensitivity to MDM2 inhibition, Cancer Res, 78, 2721, 10.1158/0008-5472.CAN-17-0949 · DOI · Paper page
  46. Synnott, 2020, COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells, Breast Cancer Res Treat, 179, 47, 10.1007/s10549-019-05435-1 · DOI · Paper page
  47. Lindemann, 2019, COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNCC through p53-dependent and -independent mechanisms, Clin Cancer Res, 25, 5650, 10.1158/1078-0432.CCR-19-0096 · DOI · Paper page
  48. Han, 2022, PROTAC Degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective, Acta Mater Med, 1, 244

Cited by

See all 60

Metadata

Authors
Brummer, T., & Zeiser, R.
Venue
Blood
Published
2024-06-27
Volume
143
Issue
26
Pages
2701-2709
ISSN
  • 0006-4971
  • 1528-0020
Cited by
60
References
18
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of the MDM2/p53 axis in antitumor immune responses. https://app.cochat.ai/papers/10.1182/blood.2023020731
The paper
Brummer, T., & Zeiser, R. (2024). The role of the MDM2/p53 axis in antitumor immune responses. Blood. https://doi.org/10.1182/blood.2023020731

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.